Who are Lebrikizumab Pen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dupilumab Prefilled Syringe, Dupilumab (SAR231893), Dupilumab step-down, Dupilumab - Dose Reduction, Dupilumab Injectable Product, Placebo matching depemokimab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lebrikizumab-pen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Lebrikizumab Pen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lebrikizumab Pen (Lebrikizumab Pen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-4 receptor antagonist; monoclonal antibody. Area: Immunology; Respiratory/Allergy.

phase 3 IL-4 receptor antagonist; monoclonal antibody IL-4Rα (Interleukin-4 receptor alpha) Immunology; Respiratory/Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Lebrikizumab Pen (Lebrikizumab Pen) — Eli Lilly and Company. Lebrikizumab is a monoclonal antibody that blocks interleukin-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lebrikizumab Pen TARGET	Lebrikizumab Pen	Eli Lilly and Company	phase 3	IL-4 receptor antagonist; monoclonal antibody	IL-4Rα (Interleukin-4 receptor alpha)
Dupilumab Prefilled Syringe	Dupilumab Prefilled Syringe	Jonathan A. Bernstein, MD	marketed	Monoclonal antibody; IL-4 receptor antagonist	IL-4 receptor alpha (IL-4Rα)
Dupilumab (SAR231893)	Dupilumab (SAR231893)	Sanofi	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab step-down	Dupilumab step-down	Nantes University Hospital	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab - Dose Reduction	Dupilumab - Dose Reduction	Johns Hopkins University	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab Injectable Product	Dupilumab Injectable Product	University of Virginia	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Placebo matching depemokimab	Placebo matching depemokimab	GlaxoSmithKline	phase 3	IL-4 receptor antagonist monoclonal antibody	IL-4Rα (Interleukin-4 receptor alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-4 receptor antagonist; monoclonal antibody class)

Eli Lilly and Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lebrikizumab Pen — Competitive Intelligence Brief. https://druglandscape.com/ci/lebrikizumab-pen. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab